{
    "clinical_study": {
        "@rank": "134612", 
        "arm_group": [
            {
                "arm_group_label": "SA237", 
                "arm_group_type": "Experimental", 
                "description": "Subcutaneous SA237"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Subcutaneous placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "The objective of this study is to evaluate the efficacy, safety, pharmacodynamic,\n      pharmacokinetic and immunogenic profiles of SA237 in patients with NMO and NMOSD"
        }, 
        "brief_title": "Efficacy and Safety Study as Monotherapy of SA237 to Treat NMO and NMOSD", 
        "completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)", 
        "condition_browse": {
            "mesh_term": "Neuromyelitis Optica"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  1. NMO or NMOSD\n\n          -  2. Age 18 to 74 years, inclusive at the time of informed consent.\n\n        Exclusion Criteria:\n\n          -  1. Pregnancy or lactation.\n\n          -  2. Evidence of other demyelinating disease or PML.\n\n          -  3. Known active infection (excluding fungal infections of nail beds or caries\n             dentium) within 4 weeks prior to baseline."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "74 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "70", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 25, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02073279", 
            "org_study_id": "SA-309JG"
        }, 
        "intervention": {
            "arm_group_label": "SA237", 
            "intervention_name": "SA237", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "February 25, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Dallas", 
                    "country": "United States", 
                    "state": "Texas"
                }
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of SA237 as Monotherapy in Patients With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)", 
        "overall_contact": {
            "email": "clinical-trials@chugai-pharm.co.jp", 
            "last_name": "Clinical trials information"
        }, 
        "overall_contact_backup": {
            "email": "sa237@chugai-pharm.co.jp", 
            "last_name": "SA237 Clinical trial"
        }, 
        "overall_official": {
            "affiliation": "Chugai Pharmaceutical", 
            "last_name": "Tatjana Lukic, MD., M.Sc.", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Time to first relapse", 
            "safety_issue": "No", 
            "time_frame": "up to approximately 27 months from first patient in"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02073279"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Annualized relapse rate", 
            "safety_issue": "No", 
            "time_frame": "up to approximately 27 months from first patient in"
        }, 
        "source": "Chugai Pharmaceutical", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Chugai Pharmaceutical", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}